{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:43:09Z","timestamp":1780670589634,"version":"3.54.1"},"reference-count":44,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Poznan University of Medical Sciences Doctoral School","award":["45092\/DGB\/2024"],"award-info":[{"award-number":["45092\/DGB\/2024"]}]},{"name":"Poznan University of Medical Sciences Doctoral School","award":["147\/2024\/MGB"],"award-info":[{"award-number":["147\/2024\/MGB"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The study aimed to analyze hsa-miR-16-5p, hsa-miR-143-3p, hsa-miR-423-5p, hsa-miR-137-3p, hsa-miR-489-5p, hsa-miR-520-3p, hsa-miR-486-5p, and hsa-miR-200a-3p expression in the serum of patients with invasive non-functioning pituitary adenomas (NFPAs) and prolactinomas, as candidates for non-invasive biomarkers. The study included 62 patients with NFPAs and 18 with macroprolactinoma who qualified for transsphenoidal surgical resection. MicroRNAs were isolated from serum samples. The expression levels of hsa-miR-16-5p, hsa-miR-143-3p, hsa-miR-423-5p, hsa-miR-137-3p, hsa-miR-489-5p, hsa-miR-520-3p, hsa-miR-486-5p, and hsa-miR-200a-3p were determined using TaqMan MicroRNA assays. The statistical analyses were performed with MedCalc. The total concentration of microRNA was significantly lower in NFPAs than in the CG (p = 0.0419). ROC curve analysis showed that the cutoff point of miRNA lower than 10.73 predicted the PA (sensitivity = 70.0%; specificity = 57.7%; AUC = 0.629; p = 0.052). No correlation between selected miRNAs and tumor type was found: hsa-miR-143-3p (p = 0.4610), hsa-miR-16-5p (p = 0.8767), and hsa-miR-423-5p (p = 0.1459). miRNA expression also did not correlate with invasiveness (cavernous or sphenoid sinus invasion, optic chiasm compression). Although the total expression of microRNA was significantly lower in NFPAs, hsa-miR-16-5p, hsa-miR-143-3p, and hsa-miR-423-5p are not useful as non-invasive biomarkers in patients with invasive non-functioning pituitary adenomas and prolactinomas.<\/jats:p>","DOI":"10.3390\/ijms26094408","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T09:08:56Z","timestamp":1746522536000},"page":"4408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MicroRNA Is Downregulated in Invasive Non-Functioning Pituitary Adenomas"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0413-2679","authenticated-orcid":false,"given":"Aleksandra","family":"Derwich-Rudowicz","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Pozna\u0144, Poland"},{"name":"Doctoral School, Poznan University of Medical Sciences, Bukowska 70, 60-812 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-8569","authenticated-orcid":false,"given":"Aleksandra","family":"\u017bbikowska","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Poznan University of Medical Sciences, Rokietnicka 5D, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-7220","authenticated-orcid":false,"given":"Marek","family":"Rucha\u0142a","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-3447","authenticated-orcid":false,"given":"Miros\u0142aw","family":"Andrusiewicz","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Poznan University of Medical Sciences, Rokietnicka 5D, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Moskal","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Poznan University of Medical Science, Przybyszewskiego 49, 60-355 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-4702","authenticated-orcid":false,"given":"Nadia","family":"Sawicka-Gutaj","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s42000-019-00168-8","article-title":"Pituitary Tumors: Epidemiology and Clinical Presentation Spectrum","volume":"19","author":"Berrocal","year":"2020","journal-title":"Hormones"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jocn.2018.10.065","article-title":"Invasive Pituitary Adenomas with Gross Total Resection: The Wait-and-See Policy during Postoperative Management","volume":"58","author":"Lv","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ecl.2020.05.008","article-title":"Aggressive Pituitary Adenomas and Carcinomas","volume":"49","author":"Ilie","year":"2020","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The Epidemiology of Aggressive Pituitary Tumors (and Its Challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical Biology of the Pituitary Adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/cen.14706","article-title":"Molecular Genetic Testing in the Management of Pituitary Disease","volume":"97","author":"Coopmans","year":"2022","journal-title":"Clin. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11154-019-09531-x","article-title":"Definition and Diagnosis of Aggressive Pituitary Tumors","volume":"21","author":"Kasuki","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_8","first-page":"762","article-title":"Management of Hormone-Secreting Pituitary Adenomas","volume":"19","author":"Mehta","year":"2017","journal-title":"Neuro. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and Management of Prolactin-Secreting Pituitary Adenomas: A Pituitary Society International Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1210\/jc.2011-3237","article-title":"Update on Pituitary Surgery","volume":"97","author":"Swearingen","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3171\/2020.3.FOCUS20247","article-title":"Introduction. Management of Pituitary Tumors: 2020 and Beyond","volume":"48","author":"Zada","year":"2020","journal-title":"Neurosurg. Focus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and Treatment of Pituitary Adenomas: A Review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2016-4061","article-title":"Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers","volume":"102","author":"Tampourlou","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chang, M., Jiang, S., Guo, X., Gao, J., Liu, P., Bao, X., Feng, M., and Wang, R. (2023). Exosomal RNAs in the Development and Treatment of Pituitary Adenomas. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1142494"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5603\/EP.a2023.0001","article-title":"MicroRNA-196a-5p Targeting LRP1B Modulates Phenotype of Thyroid Carcinoma Cells","volume":"74","author":"Hu","year":"2023","journal-title":"Endokrynol. Pol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lyu, L., Li, H., Chen, C., Yu, Y., Wang, L., Yin, S., Hu, Y., Jiang, S., Ye, F., and Zhou, P. (2022). Exosomal miRNA Profiling Is a Potential Screening Route for Non-Functional Pituitary Adenoma. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.771354"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"dmm047662","DOI":"10.1242\/dmm.047662","article-title":"miRNA Interplay: Mechanisms and Consequences in Cancer","volume":"14","author":"Hill","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21873\/anticanres.13077","article-title":"MicroRNA Expression in the Progression and Aggressiveness of Papillary Thyroid Carcinoma","volume":"39","author":"Zembska","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jcp.20282","article-title":"miR-15a and miR-16-1 down-Regulation in Pituitary Adenomas","volume":"204","author":"Bottoni","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gallo, A., Tandon, M., Alevizos, I., and Illei, G.G. (2012). The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030679"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/JAD-2008-14103","article-title":"Identification of miRNA Changes in Alzheimer\u2019s Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways","volume":"14","author":"Cogswell","year":"2008","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_22","first-page":"1","article-title":"Cell-Secreted Vesicles in Equine Ovarian Follicular Fluid Contain miRNAs and Proteins: A Possible New Form of Cell Communication Within the Ovarian Follicle1","volume":"86","author":"Veeramachaneni","year":"2012","journal-title":"Biol. Reprod."},{"key":"ref_23","first-page":"207","article-title":"Clinical Predictive Value of Control Attenuation Parameters in Combination with miR-192-5p in Patients with Acute Pancreatitis in Nonalcoholic Fatty Liver Disease","volume":"75","author":"Hu","year":"2024","journal-title":"Endokrynol. Pol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cr.2008.282","article-title":"Characterization of microRNAs in Serum: A Novel Class of Biomarkers for Diagnosis of Cancer and Other Diseases","volume":"18","author":"Chen","year":"2008","journal-title":"Cell Res."},{"key":"ref_25","first-page":"1235","article-title":"MicroRNA-16\/VEGFR2\/P38\/NF-\u03baB Signaling Pathway Regulates Cell Growth of Human Pituitary Neoplasms","volume":"39","author":"Lu","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ncrna.2021.06.004","article-title":"Differential Non-Coding RNAs Expression Profiles of Invasive and Non-Invasive Pituitary Adenomas","volume":"6","author":"Beylerli","year":"2021","journal-title":"Non-Coding RNA Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1210\/jc.2018-02479","article-title":"Comprehensive Analysis of Circulating miRNAs in the Plasma of Patients With Pituitary Adenomas","volume":"104","author":"Darvasi","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","first-page":"533","article-title":"Identification of microRNAs Associated with the Aggressiveness of Prolactin Pituitary Tumors Using Bioinformatic Analysis","volume":"42","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.1210\/jc.2018-02544","article-title":"MiR-137\u2019s Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway","volume":"104","author":"Lei","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","first-page":"10969","article-title":"MicroRNA-143 Shows Tumor Suppressive Effects through Inhibition of Oncogenic K-Ras in Pituitary Tumor","volume":"10","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1541-7786.MCR-23-0015","article-title":"Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation","volume":"21","author":"Yagi","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ju, Y., Choi, G.-E., Lee, M.W., Jeong, M., Kwon, H., Kim, D.H., Kim, J., Jin, H., Lee, K.E., and Hyun, K.-Y. (2023). Identification of miR-143-3p as a Diagnostic Biomarker in Gastric Cancer. BMC Med. Genom., 16.","DOI":"10.21203\/rs.3.rs-2497525\/v1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3892\/or.2021.7953","article-title":"Combination of miR-143 and miR-506 Reduces Lung and Pancreatic Cancer Cell Growth through the Downregulation of Cyclin-dependent Kinases","volume":"45","author":"Hossian","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_34","first-page":"866","article-title":"MiR-143-3p Suppresses the Progression of Ovarian Cancer","volume":"10","author":"Shi","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Armstrong, L., Willoughby, C.E., and McKenna, D.J. (2023). Targeting of AKT1 by miR-143-3p Suppresses Epithelial-to-Mesenchymal Transition in Prostate Cancer. Cells, 12.","DOI":"10.3390\/cells12182207"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.canlet.2014.10.003","article-title":"MiR-132, miR-15a and miR-16 Synergistically Inhibit Pituitary Tumor Cell Proliferation, Invasion and Migration by Targeting Sox5","volume":"356","author":"Renjie","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_37","first-page":"2491","article-title":"miR-16 Regulates Proliferation and Apoptosis of Pituitary Adenoma Cells by Inhibiting HMGA2","volume":"17","author":"Niu","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2008-1451","article-title":"MicroRNAs Differentially Expressed in ACTH-Secreting Pituitary Tumors","volume":"94","author":"Amaral","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e8516858","DOI":"10.1155\/2019\/8516858","article-title":"Identification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas","volume":"2019","author":"Zhao","year":"2019","journal-title":"Int. J. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3892\/mmr.2017.6696","article-title":"MYC and hsa-miRNA-423-5p as Biomarkers in Nasopharyngeal Carcinoma Revealed by miRNA-mRNA-pathway Network Integrated Analysis","volume":"16","author":"Tian","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12957-021-02383-3","article-title":"Potential Biomarkers of miRNA in Non-Functional Pituitary Adenomas","volume":"19","author":"Zhang","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_42","first-page":"e928","article-title":"Study Designs in Medical Research and Their Key Characteristics","volume":"92","author":"Nowak","year":"2023","journal-title":"J. Med. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.20883\/medical.e700","article-title":"Publication Ethics of Human Studies in the Light of the Declaration of Helsinki\u2014A Mini-Review","volume":"91","author":"Guzik","year":"2022","journal-title":"J. Med. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tok\u0142owicz, M., \u017bbikowska, A., Janusz, P., Kotwicki, T., Andrusiewicz, M., and Kotwicka, M. (2023). MicroRNA Expression Profile Analysis in Human Skeletal Muscle Tissue: Selection of Critical Reference. Biomed. Pharmacother., 162.","DOI":"10.1016\/j.biopha.2023.114682"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:27:41Z","timestamp":1760030861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26094408"],"URL":"https:\/\/doi.org\/10.3390\/ijms26094408","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}